MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

scientific article published on 18 March 2018

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJMOA1801993
P698PubMed publication ID29552975

P50authorPhog AllenQ2088566
Yemisi TakwoingiQ30004015
Jonathan DeeksQ47705879
Antti RannikkoQ55079166
Samir S TanejaQ56516562
Arnauld VillersQ56531008
Boris HadaschikQ60647747
Caroline MooreQ62606989
Mark EmbertonQ63968187
Alberto BrigantiQ67191563
Laurence KlotzQ83824697
Veeru KasivisvanathanQ88094435
Peter A PintoQ90059716
Scott E EggenerQ91336387
Inderbir S. GillQ95169970
P2093author name stringLance A Mynderse
Stephen Morris
Monique J Roobol
Norman R Williams
Alex Freeman
Richard G Hindley
Valeria Panebianco
Lars Budäus
Shonit Punwani
Jim C Hu
Giles Hellawell
Franck Bladou
Daniel Margolis
Chris Brew-Graves
Sébastien Crouzet
Alain Ruffion
Francesco Giganti
Grégoire Robert
Paras B Singh
Silvan Boxler
Jaspal Virdi
Maneesh Ghei
Markku H Vaarala
Wulphert Venderink
Geert M Villeirs
Marcelo Borghi
PRECISION Study Group Collaborators
P407language of work or nameEnglishQ1860
P921main subjectmagnetic resonance imagingQ161238
prostate cancerQ181257
P577publication date2018-03-18
P1433published inThe New England Journal of MedicineQ582728
P1476titleMRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Reverse relations

cites work (P2860)
Q58691149A Festschrift in Honor of Edward M. Messing, MD, FACS
Q63965910A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy
Q115033160A better way to biopsy in prostate cancer
Q89701424A case report of multiple primary prostate tumors with differential drug sensitivity
Q57824787A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification
Q92740583A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection
Q89639784A novel biparametric magnetic resonance imaging sequence provides a more efficient and similarly efficacious method of risk stratifying men clinically suspected of having prostate cancer
Q93112102A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies
Q90039554A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate
Q93134999A review of optimal prostate biopsy: indications and techniques
Q91617685A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy
Q101471273AUTHOR REPLY
Q92258193Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer
Q64262666Active surveillance for non-muscle invasive bladder cancer
Q99403833Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer
Q99411604Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study
Q52572975Adoption of Pre-Biopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States.
Q93360733Advances in prostate cancer imaging
Q92863027Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer-positive biopsies
Q59794433An annotated test-retest collection of prostate multiparametric MRI
Q92449330Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients
Q91787524Are we ready to adopt the European Association of Urology recommendations on multiparametric magnetic resonance imaging in the early detection of prostate cancer?
Q64261177Artificial intelligence at the intersection of pathology and radiology in prostate cancer
Q62490912Artificial intelligence in cancer imaging: Clinical challenges and applications
Q92732671Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction
Q92662015Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4
Q90831294Author reply
Q63884154BRCA2 and Other DDR Genes in Prostate Cancer
Q101476441Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test
Q92052777CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
Q58554027Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation
Q97904987Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?
Q92065389Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI
Q89555141Cancer Progress and Priorities: Prostate Cancer
Q91640542Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening
Q92179430Characterizing the learning curve of MRI-US fusion prostate biopsies
Q64097808Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies
Q89235799Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion
Q90523248Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis
Q97559360Combined MRI-targeted plus systematic confirmatory biopsy improves risk stratification for patients enrolling on active surveillance for prostate cancer
Q91685412Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance
Q92038496Commentary RE: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer
Q92473706Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis
Q58570433Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer
Q95261047Comparison of clinically significant prostate cancer detection by MRI cognitive biopsy and in-bore MRI-targeted biopsy for naïve biopsy patients
Q90414258Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances
Q91958397Concordance and Performance of 4Kscore® and SelectMDx® for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer
Q63966136Constructing and Pilot Testing a Novel Prostate Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Phantom
Q92213705Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings
Q90048692Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study
Q92861968Detection of individual prostate cancer via multiparametric magnetic resonance imaging in own material - initial experience
Q92397846Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort
Q89698266Diagnostic Accuracy and Value of Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging
Q92662009Diagnostic Performance of Prostate Multiparametric Magnetic Resonance Imaging in African-American Men
Q64973435Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.
Q91855085Difference in MRI-guided biopsy cancer detection rates between individual clinicians
Q92760179Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
Q92374355EDITORIAL COMMENT
Q101471271EDITORIAL COMMENT
Q64981272Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer.
Q92023285Effects of "real life" prostate MRI inter-observer variability on total needle samples and indication for biopsy
Q59506757Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer
Q94528362Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer
Q95261507Establishing a novel prediction model for improving the positive rate of prostate biopsy
Q93177852Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy
Q95261579Evolution of prostate cancer diagnosis: retrospective analysis of magnetic resonance imaging/ultrasound fusion guided biopsies protocol in routine practice and patients management
Q93334545Exclusive MRI-targeted biopsy: not so fast
Q95933734External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study
Q89843695External validation of the Martini nomogram for prediction of side-specific extraprostatic extension of prostate cancer in patients undergoing robot-assisted radical prostatectomy
Q92003889Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer
Q93025020Financial implications of biparametric prostate MRI
Q91766786Focal Ablation of Prostate Cancer
Q60920500Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives
Q89686768Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI
Q88766160Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?
Q93182653Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template
Q93011457Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis
Q64231463Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer
Q92234351Genomics of lethal prostate cancer at diagnosis and castration resistance
Q92596399Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer
Q89955655Histomorphological analysis of false positive PI-RADS 4 and 5 lesions
Q57457179Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate
Q57725405How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer?
Q57171336Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications
Q60923446Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification
Q99569317Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance
Q92397839Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies
Q57111662Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy
Q90257493Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns
Q93147992Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance
Q92710180Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features
Q64910506In-bore biopsies of the prostate assisted by a remote-controlled manipulator at 1.5 T.
Q93101418Increasing the use of active surveillance for prostate cancer in younger men
Q93001050Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies
Q64105020Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model
Q90005516Inflammation appears as high Prostate Imaging-Reporting and Data System scores on prostate magnetic resonance imaging (MRI) leading to false positive MRI fusion biopsy
Q92090246Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesions
Q90690736Intra- and interreader reproducibility of PI-RADSv2: A multireader study
Q58551655Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy
Q104073765Is a targeted biopsy-only approach for prostate cancer diagnosis ready for the prime time?
Q92151543Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL?
Q57105378Landmarks in prostate cancer
Q64078907Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada
Q88334686MRI improves diagnosis
Q90989090MRI in active surveillance: a critical review
Q57107955MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years
Q90044063MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Q57105670MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature
Q92205706MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: A feasibility follow-up study
Q100316322MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort
Q88579261Magnet Before the Needle Commentary on: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis (PRECISION Trial)
Q90058228Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer
Q89639772Magnetic resonance imaging sequences for prostate cancer triage: two is a couple, three is a crowd?
Q91815652Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations
Q92955380Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management
Q92962785Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review
Q92051720Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions
Q93086191Multimodality Imaging of Prostate Cancer
Q91969165Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Q89543243Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain
Q92345413Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
Q89783216New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions
Q94546975New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers
Q64320006New oral anti-coagulation drugs and prostate biopsy: a call for guidelines
Q100528986Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)
Q96123493Oncological control following partial gland ablation for intermediate-risk prostate cancer
Q93182732Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy
Q91634714Optimization and repeatability of multipool chemical exchange saturation transfer MRI of the prostate at 3.0 T
Q92830892PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design
Q102319482PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?
Q89181551PRECISION delivers on the PROMIS of mpMRI in early detection
Q92167793PROSTATEx Challenges for computerized classification of prostate lesions from multiparametric magnetic resonance images
Q58107966PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics
Q96813857Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling
Q90199650Patient-Centered Outcomes From Multiparametric MRI and MRI-Guided Biopsy for Prostate Cancer: A Systematic Review
Q92722967Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection
Q59813234Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy
Q90377740Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy
Q92535853Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
Q89396666Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
Q99569316Post prostatectomy Pathologic Findings of Patients with Clinically Significant Prostate Cancer and no Significant PI-RADS Lesions on Preoperative Magnetic Resonance Imaging
Q90464069Practice changing for prostate cancer: a vision of the future
Q94475404Predicting clinically significant prostate cancer from quantitative image features including compressed sensing radial MRI of prostate perfusion using machine learning: comparison with PI-RADS v2 assessment scores
Q64085522Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
Q94550790Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system
Q96303424Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI
Q92872291Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS
Q92824548Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
Q90034400Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery
Q103798598Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer
Q90466669Prognostic value of the SPOP mutant genomic subclass in prostate cancer
Q89768162Prostate Cancer Academy 2019 Selected Summaries
Q90609622Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men
Q57106542Prostate Cancer in Primary Care
Q89125002Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions
Q90274615Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands
Q58565438Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK
Q91632680Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial
Q94550311Prostate cancer screening research can benefit from network medicine: an emerging awareness
Q57106301Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
Q64115030Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments
Q92207247Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates
Q90729984Quantifying the effect of biopsy lateral decubitus patient positioning compared to supine prostate MRI scanning on prostate translocation and distortion
Q90660060Quantitative MRI or Machine Learning for Prostate MRI: Which Should You Use?
Q92625861Re: Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer
Q102219062Recent Advances and Current Role of Transperineal Prostate Biopsy
Q91205471Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings
Q104610455Reply to The risk factors of upgrading in prostate cancer
Q58562144Rethinking active surveillance for prostate cancer in African American men
Q97643274Rethinking prostate cancer screening: could MRI be an alternative screening test?
Q95261546Robotic-assisted magnetic resonance imaging ultrasound fusion results in higher significant cancer detection compared to cognitive prostate targeting in biopsy naive men
Q90491182Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer
Q91896696Role of novel imaging in the management of prostate cancer
Q57107930Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance
Q100395438Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia
Q90450297Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging
Q100517496Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications
Q98881626Sub-optimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy
Q92375021Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications
Q103825407Target Biopsy and Core Number in Prostate Biopsy
Q89925192Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy
Q57109743Targets missed: predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy
Q92442572Teaching Urologists "How to Read Multi-Parametric Prostate MRIs Using PIRADSv2": Results of an iBook Pilot Study
Q94521779Telomere-based risk models for the early diagnosis of clinically significant prostate cancer
Q93385582Template for MR Visualization and Needle Targeting
Q90439990Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
Q91935327The Accuracy of Prostate Magnetic Resonance Imaging Interpretation: Impact of the Individual Radiologist and Clinical Factors
Q91564648The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy
Q92029338The First In Vivo Needle-Based Optical Coherence Tomography in Human Prostate: A Safety and Feasibility Study
Q57107304The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points
Q98224376The Role of Multiparametric MRI and MRI-targeted Biopsy in Detecting Clinically Significant Prostate Cancer in the Community Setting: A Retrospective Study
Q64074113The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification
Q92689529The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density
Q92454410The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations
Q57107312The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?
Q92705843The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods
Q91123470The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy
Q91808454The current role of prostate multiparametric magnetic resonance imaging
Q91526392The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging
Q98302233The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings-Implications for the COVID-19 era
Q102379251The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients with prostate cancer
Q57105057The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging
Q88770500The pendulum swings back: Screening for prostate cancer in 2018
Q92575413The primacy of multiparametric MRI in men with suspected prostate cancer
Q90665408The pros and cons of screening
Q96135129The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer
Q93081310The role of Prostate Imaging Reporting and Data System score in Gleason 3 + 3 active surveillance candidates enrollment: a diagnostic meta-analysis
Q102063210The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial
Q92637533The role of multiparametric MRI in biopsy-naive prostate cancer
Q104504831The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy
Q92032404Three things about Gleason grading that just about everyone believes but that are almost certainly wrong
Q64107477Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study
Q92341993To see or not to see - what renders prostate cancer visible?
Q89728801Transperineal free-hand mpMRI fusion-targeted biopsies under local anesthesia: technique and feasibility from a single-centre prospective study
Q64243026Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
Q91120894Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer
Q93334539Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study
Q90730005Utility of digital rectal examination in a population with prostate cancer treated with active surveillance
Q92488218Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial
Q90292338What are roles of multiparametric magnetic resonance imaging prior to transurethral resection of bladder tumor?
Q104517654[French ccAFU guidelines - update 2020-2022: prostate cancer]
Q90582185[Imaging in individualized uro-oncology]

Search more.